We are advancing a growing portfolio of off-the-shelf, optimally engineered NK cell therapy candidates that express not only a specific tumor antigen targeted CAR, but also have undergone different gene edits (e.g. CISH KO, CD38 KO and TGFβR2 KO) and additional construct features including a TNF-related apoptosis-inducing ligand variant (TRAILv) targeting the death receptor pathway via DR4 or DR5.
This pioneering approach has the clear goal to maximize the cytotoxic potential, metabolic health and persistence of the engineered NK cells.
Program | Construct Targets and Enhancements | Indication | Research | Lead Optimization | IND Enabling |
---|
ONKT105 | Non CAR construct CISHKO +/- TGF scIL-15 | Various Hematological and Solid Tumors | 100 | 100 | 85 |
Highly functional, edited cord derived NK cell therapy programs in combination with mAb or NK cell engagers |
ONKT102 | CD38 CAR CD38KO CISHKO | Relapsed / Refactory Multiple Myeloma | 100 | 100 | 90 |
ONKT104 | CLL-1 CAR CISHKO scIL-15 | AML | 90 |
CAR-NK cell therapy programs |
ONKT103 | MUC-1 CAR CISHKO +/- TGF scIL-15 | Pancreatic, Ovarian, TN Breast | 90 |
We are in the early phases of exploring ONKT106, a program for highly functional CISH KO iPSC cells.